CTOs on the Move

Lyniate

www.lyniate.com

 
Lyniate offers industry-leading interoperability solutions that deliver simple and seamless integration of all health data. With two Best-in-KLAS products, Lyniate Corepoint and Lyniate Rhapsody, we established a proven reputation on which we continue to build adaptable interoperability solutions that connect the healthcare ecosystem to unlock the full potential of data. We partner with providers, health plans, and health tech solutions around the world to enable rapid, reliable, and scalable interoperability, both vertically and horizontally, on-premises and in the cloud.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.lyniate.com
  • 100 High Street Suite 1560
    Boston, MA USA 02110
  • Phone: 214.618.7000

Executives

Name Title Contact Details
Sameer Sule
Chief Information Security Officer and VP, Compliance Profile
Scott Galbari
President, Chief Operating Officer, and Chief Information Security Officer Profile
Matt Rice
Director Of Information Technology Profile

Similar Companies

Mahoning County

Mahoning County is a Youngstown, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oakcrest Manors

Oakcrest Manors is a Jenison, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mercator MedSystems

Mercator MedSystems is a San Leandro, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GeoH

Indianapolis-based GeoH is a Software as a Service (SaaS) company that provides an end-to-end home care software solution. The company was named one of the Top Ten Home Healthcare Solutions Providers in 2020 by Healthcare Tech Outlook. The company was created by agency owners and technologists with more than 20 years of experience working in home health care and technology.

RaNA Therapeutics

RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.